Validation shows association of genomic alterations with progression-free survival in newly diagnosed multiple myeloma, suggesting importance of updated risk classification.
Key Points
Validation demonstrates that genomic alterations significantly impact progression-free survival rates in newly diagnosed multiple myeloma patients.
The presence of TP53 mutations was notably assessed in 287 patients, revealing crucial prognostic information.
Analysis was conducted across multiple clinical trials, evaluating the Consensus Genomic Staging system's effectiveness in risk assessment.
Findings support the integration of advanced genomic techniques in multiple myeloma diagnostic processes for more accurate patient stratification.
Cite This Study
Sanchez-Tabernero et al. (2025) studied this question.